Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Is T. Rowe Price Health Sciences Fund (PRHSX) Worth Another Look?

T. Rowe Price Health Sciences (PRHSX) a Zacks Ranked #2 (Buy) was incepted in December 1995 and is managed by T.Rowe Price Associates. PRHSX’s main objective is long-term capital appreciation. PRHSX invests at least 80% of its net assets in common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. PRHSX may invest in companies of any size, the majority of fund assets are invested in large and mid capitalization companies.

This Sector - Health product, as of the last filing, allocates their fund in two major groups; Small Growth and Large Growth. Further, as of the last filing, Allergan, Alexion Pharmaceuticals, Inc. and UnitedHealth Group Incorporated were the top holdings for PRHSX.

T. Rowe Price Health Sciences, managed by T. Rowe Price, carries an expense ratio of 0.76%. Moreover, PRHSX requires a minimal initial investment of $2,500.

PRHSX has a history of strong total returns for over 10 years. Specifically, the fund’s returns over the 3, 5 year benchmarks; 3 year 19.26% and 5 year 20.01%. To see how this fund performed compared in its category, please click here.

PRHSX’s performance, as of the last filing, when compared to funds in its category was in the top 43% in 1 year, top 8% over the past 3 years, and in the 9% over the past 5 years.

Zacks Premium

To see the Zacks Mutual Fund Rank for the funds you’re interested in —plus, gain access to the Zacks Rank for your stocks and ETFs; Premium Screens; Equity Research Reports; Focus List portfolio of 50-longer-term stocks and more— start your 30-day free trial to Zacks Premium.


View All Zacks #1 Ranked Mutual Funds
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Get Your Free (PRHSX): Fund Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research